ONCOSPIRE GENOMICS

Oncospire Genomics is a joint venture with the singular goal of improving cancer by discovering and commercializing diagnostic tests that leverage next-generation sequencing.

Who We Are

CGI’S JOINT VENTURE WITH MAYO CLINIC

Launched in 2013, Oncospire was established as an equally owned joint venture between Cancer Genetics, Inc. and Mayo Clinic. Focussed on developing and commercializing next generation sequencing (NGS) panels for areas of critical unmet need in Oncology, Oncospire Genomics is currently developing targeted NGS diagnostic panels for solid tumors and hematological cancers, including lung cancer, multiple myeloma, and follicular lymphoma.

LUNG CANCER

More than 1.6 million new cases of lung cancer are diagnosed globally each year- making lung cancer the second most commonly diagnosed cancer. In the United States, lung cancer represents more than 25% of cancer deaths. Despite its significant global impact on healthcare, to date, only a handful of biomarkers have been identified for this disease. Recognizing that’s earlier diagnosis and better differentiation is critical to improving patient outcomes, Oncospire Genomics is focussed on delivering NGS panels that will provide comprehensive lung cancer insight.

MULTIPLE MYELOMA

There is a significant need for improved diagnostics for multiple myeloma (MM). Currently available tests are expensive, inasive, and often require mulltiple biopsies. Because next generation sequencing allows for the assessment of a number of genomic biomarkers with a single test and requires less specimen material, NGS can improve cost and reduce invasive testing. Oncospire Genomics is working to develop a test that would improve early detection by predicting transformation from Monoclonal Gammopathy of Undetermined Significance (MGUS) to multiple myeloma, and better prognose those patients already confirmed with the disease.

FOLLICULAR LYMPHOMA

The second most common form of lymphoma in the US, Follicular Lymphoma represents approximately 30% of all non-Hodgkin lymphomas, Oncospire Genomics is working to develop an NGS- based test that can be better identify at-risk patients’ likelihood of disease progression, provide more cost-effective monitoring, and eventually become a standard for predicting FL patient outcome.

Insights From Our Partners

"Our collaborative approach to impacting patient care is a blueprint for health care innovation with the potential to revolutionize patient management in a disease specific manner. By bringing together Mayo Clinic's team of world-class researchers and clinicians with expertise from CGI, Oncospire will soon be delivering oncology diagnostics and insights that can be integrated into the clinical practice to improve patient outcomes."

− KEITH STEWART , M.B. , CH.B.
CARLSON AND NELSON ENDOWED DIRECTOR
MAYO CLINIC CENTER FOR INDIVIDUALIZED MEDICINE
Contact Us

For Inquiries Contact Panna Sharma at 201.528.9200 or drop us an email below:

Your Name (required)

Your Email (required)

Subject

Your Message